Janssen Scientific Affairs enrolls 1st patient into Crohn's disease treatment study — 4 insights

Janssen Scientific Affairs enrolled the first patient into its Seavue trial, which aims to compare the effectiveness of Stelara and Humira in treating patients with moderate to severe Crohn's disease.

Here's what you should know:

1. Janssen is conducting the phase 3 trial to create comparative data between the two CD treatment options.

2. Researchers plan to enroll approximately 350 patients into the study, which will take place at up to 100 worldwide sites.

3. The study will conclude in 2020.

4. The treatment phase of the study will take 52 weeks, with a follow-up phase of 76 weeks.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast